Drug Trial Radar · NCT05791201
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
7
Actual
Start
May 16, 2023
Primary completion
Mar 12, 2027
Study completion Mar 12, 2027
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Mar 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Conditions
- Type 1 Diabetes
Interventions
VX-264Drug
Allogeneic human stem cell-derived islets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A and Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to 24 months
- Part B: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT)Time frame: From Baseline and at Day 90
Locations
16 sites in 7 countries. Site status is shown where the registry gives one.
UHealth Diabetes Research Institute
Miami, Florida
University of Chicago
Chicago, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center Montefiore
Pittsburgh, Pennsylvania
University of Wisconsin
Madison, Wisconsin
University of Alberta, Edmonton
Edmonton, Canada
Montreal Clinical Research Institute
Montreal, Canada
Toronto General Hospital (TGH)
Toronto, Canada
Vancouver General Hospital
Vancouver, Canada
Dresden Center for Islet Transplantation
Dresden, Germany
IRCCS Ospedale San Raffaele
Milan, Italy
Leiden University
Leiden, Netherlands
Hopiteaux Universitaires de Geneve
Geneva, Switzerland
Royal Victoria Infirmary
Newcastle upon Tyne, United Kingdom
Churchill Hospital
Oxford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.